1. Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)
- Author
-
Hongyun Huang, Wise Young, Lin Chen, Shiqing Feng, Ziad M. Al Zoubi, Hari Shanker Sharma, Hooshang Saberi, Gustavo A. Moviglia, Xijing He, Dafin F. Muresanu, Alok Sharma, Ali Otom, Russell J. Andrews, Adeeb Al-Zoubi, Andrey S. Bryukhovetskiy, Elena R. Chernykh, Krystyna Domańska-Janik, Emad Jafar, W. Eustace Johnson, Ying Li, Daqing Li, Zuo Luan, Gengsheng Mao, Ashok K. Shetty, Dario Siniscalco, Stephen Skaper, Tiansheng Sun, Yunliang Wang, Lars Wiklund, Qun Xue, Si-Wei You, Zuncheng Zheng, Milan R. Dimitrijevic, W. S. El Masri, Paul R. Sanberg, Qunyuan Xu, Guoming Luan, Michael Chopp, Kyoung-Suok Cho, Xin-Fu Zhou, Ping Wu, Kai Liu, Hamid Mobasheri, Seiji Ohtori, Hiroyuki Tanaka, Fabin Han, Yaping Feng, Shaocheng Zhang, Yingjie Lu, Zhicheng Zhang, Yaojian Rao, Zhouping Tang, Haitao Xi, Liang Wu, Shunji Shen, Mengzhou Xue, Guanghong Xiang, Xiaoling Guo, Xiaofeng Yang, Yujun Hao, Yong Hu, Jinfeng Li, Qiang AO, Bin Wang, Zhiwen Zhang, Ming Lu, and Tong Li
- Subjects
Medicine - Abstract
Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version “Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)”. The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility.
- Published
- 2018
- Full Text
- View/download PDF